Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 5 | 2018 | 240 | 1.850 |
Why?
|
| Lung Neoplasms | 7 | 2021 | 551 | 1.780 |
Why?
|
| Radiation Oncology | 5 | 2022 | 14 | 1.720 |
Why?
|
| Radiosurgery | 5 | 2018 | 37 | 1.370 |
Why?
|
| Brachytherapy | 2 | 2013 | 46 | 0.790 |
Why?
|
| Employment | 3 | 2022 | 40 | 0.730 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 368 | 0.730 |
Why?
|
| Internship and Residency | 3 | 2022 | 215 | 0.710 |
Why?
|
| Surgical Oncology | 1 | 2020 | 6 | 0.670 |
Why?
|
| Physicians, Women | 1 | 2020 | 15 | 0.660 |
Why?
|
| Medical Oncology | 1 | 2020 | 44 | 0.640 |
Why?
|
| Faculty, Medical | 1 | 2020 | 44 | 0.640 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 133 | 0.610 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 17 | 0.580 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 52 | 0.580 |
Why?
|
| Lymph Nodes | 2 | 2016 | 73 | 0.570 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 140 | 0.560 |
Why?
|
| Pneumonectomy | 1 | 2018 | 77 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 172 | 0.540 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 5 | 0.530 |
Why?
|
| Mycosis Fungoides | 1 | 2016 | 6 | 0.530 |
Why?
|
| Electrons | 1 | 2016 | 17 | 0.520 |
Why?
|
| Radiotherapy | 1 | 2016 | 33 | 0.520 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 79 | 0.490 |
Why?
|
| Radiotherapy Dosage | 4 | 2017 | 100 | 0.470 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 6 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 177 | 0.400 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 1 | 0.390 |
Why?
|
| Organs at Risk | 1 | 2012 | 7 | 0.390 |
Why?
|
| Melanoma | 1 | 2012 | 59 | 0.370 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 4842 | 0.360 |
Why?
|
| Humans | 17 | 2022 | 27221 | 0.350 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 139 | 0.310 |
Why?
|
| Female | 10 | 2020 | 15312 | 0.300 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 350 | 0.290 |
Why?
|
| United States | 5 | 2022 | 2076 | 0.280 |
Why?
|
| Adult | 5 | 2020 | 7939 | 0.270 |
Why?
|
| Survival Rate | 2 | 2018 | 344 | 0.260 |
Why?
|
| Male | 9 | 2018 | 14854 | 0.250 |
Why?
|
| Aged | 8 | 2022 | 9113 | 0.250 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 93 | 0.240 |
Why?
|
| Middle Aged | 7 | 2018 | 9059 | 0.230 |
Why?
|
| Tumor Burden | 2 | 2015 | 28 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2018 | 3526 | 0.210 |
Why?
|
| Young Adult | 2 | 2018 | 2030 | 0.180 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 179 | 0.160 |
Why?
|
| Leadership | 1 | 2020 | 92 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2022 | 1785 | 0.150 |
Why?
|
| Career Choice | 1 | 2018 | 26 | 0.150 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2018 | 3 | 0.150 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 12 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2018 | 59 | 0.140 |
Why?
|
| SEER Program | 1 | 2018 | 42 | 0.140 |
Why?
|
| Age Distribution | 1 | 2018 | 87 | 0.140 |
Why?
|
| Prognosis | 2 | 2018 | 804 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 101 | 0.140 |
Why?
|
| Professional Practice Location | 1 | 2017 | 2 | 0.140 |
Why?
|
| Academies and Institutes | 1 | 2017 | 11 | 0.140 |
Why?
|
| Censuses | 1 | 2017 | 9 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 94 | 0.140 |
Why?
|
| Patient Safety | 1 | 2017 | 38 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 105 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 903 | 0.130 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 9 | 0.130 |
Why?
|
| Radiometry | 1 | 2016 | 25 | 0.130 |
Why?
|
| Mediastinum | 1 | 2016 | 6 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2017 | 123 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 199 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2016 | 36 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 331 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1802 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 352 | 0.120 |
Why?
|
| Age Factors | 1 | 2017 | 776 | 0.110 |
Why?
|
| Orbital Pseudotumor | 1 | 2013 | 1 | 0.110 |
Why?
|
| Optic Nerve Glioma | 1 | 2013 | 1 | 0.110 |
Why?
|
| Graves Ophthalmopathy | 1 | 2013 | 1 | 0.110 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2013 | 2 | 0.110 |
Why?
|
| Meningioma | 1 | 2013 | 17 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2013 | 15 | 0.110 |
Why?
|
| Macula Lutea | 1 | 2012 | 3 | 0.100 |
Why?
|
| Optic Disk | 1 | 2012 | 3 | 0.100 |
Why?
|
| Retina | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 1903 | 0.100 |
Why?
|
| Lens, Crystalline | 1 | 2012 | 33 | 0.100 |
Why?
|
| Software | 1 | 2012 | 61 | 0.100 |
Why?
|
| Adolescent | 1 | 2018 | 2183 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 52 | 0.100 |
Why?
|
| Equipment Design | 1 | 2012 | 136 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3547 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 88 | 0.060 |
Why?
|
| Medicare | 1 | 2022 | 123 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 169 | 0.040 |
Why?
|
| Population Density | 1 | 2018 | 7 | 0.040 |
Why?
|
| Job Application | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cities | 1 | 2018 | 17 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2018 | 27 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2018 | 23 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2018 | 257 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 63 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 667 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 38 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 3 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 37 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 1156 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 462 | 0.020 |
Why?
|